Beyond 5,000 Implants: Elevation Spine Redefines Cervical Fusion

MONTEREY, CA – June 25, 2026 – In the high-stakes world of medical devices, milestones are more than just numbers—they are validation. For Monterey-based Elevation Spine, surpassing 5,000 implantations of its Saber-C Anterior Cervical Fusion System is a significant validator, signaling a potent combination of surgical acceptance, market traction, and technological resonance. The achievement reflects a growing shift in how surgeons approach one of the most common spinal procedures, the Anterior Cervical Discectomy and Fusion (ACDF).

“Five thousand implantations is more than a number. It’s five thousand data points from surgeons in the OR telling us what works, what they need, and where to go next,” said Charlie Gilbride, CEO of Elevation Spine, in a recent announcement. This philosophy of iterative, surgeon-led refinement is at the core of the company's strategy, and it appears to be paying dividends in a fiercely competitive field.

Streamlining a 'Gold Standard' Procedure

The ACDF procedure is the gold standard for treating cervical degenerative disc disease and herniated discs. For decades, the conventional method involved removing a damaged disc, inserting a spacer (or cage) to restore height, and securing the vertebrae with a separate anterior plate and screws. While effective, this multi-step process can increase operative time and potentially lead to complications like postoperative dysphagia (difficulty swallowing) due to the plate's profile irritating surrounding soft tissues.

Elevation Spine’s Saber-C system is engineered to directly address these challenges. It belongs to a class of devices known as zero-profile, or integrated, fixation systems. The core innovation is the fusion of the interbody spacer and the fixation plate into a single, cohesive unit. This integrated design eliminates the need for a separate, prominent anterior plate, streamlining the surgical workflow.

What sets Saber-C apart is its proprietary Saber™ in-line spike fixation technology. The system allows a surgeon to deploy small, sharp spikes into the vertebral bodies above and below the disc space in a single, simultaneous step. This creates immediate, robust stability without the complexity of placing and angling individual screws. For surgeons like Dr. Tien Le of the Total Spine & Brain Institute, the benefits are tangible. “The spike fixation deploys predictably, the workflow is clean, and I’m not managing a separate plating step,” he noted. “Five thousand implantations speaks for itself, this system has earned its track record.”

Clinical research on zero-profile devices supports these anecdotal benefits. Multiple meta-analyses and studies have shown that such integrated systems are associated with a significantly lower incidence of postoperative dysphagia compared to traditional plate-and-cage constructs. By reducing the hardware's anterior profile, there is less potential for irritation of the esophagus, a common cause of this uncomfortable side effect.

Carving a Niche in a Crowded Market

Achieving this milestone is particularly noteworthy given the market dynamics. The global spinal fusion device market, estimated at $8.9 billion in 2024, is dominated by industry giants like Medtronic, Johnson & Johnson (DePuy Synthes), and Stryker. In this environment, smaller innovators must differentiate through superior technology and a clear value proposition.

Elevation Spine has done just that by focusing on a specific technological niche and executing it effectively. The Saber-C system’s clearance from the FDA as an anterior cervical plate—a classification not all zero-profile devices achieve—gives it a stronger regulatory footing than standalone interbody devices. This allows surgeons to use it with the same confidence in stability as a traditional plate while gaining the procedural efficiencies of an integrated system. The platform’s versatility, offering both spike and screw options for a total of seven fixation points, provides a level of customizability that appeals to a wide range of surgical preferences and patient anatomies.

The 5,000-implant figure serves as powerful social proof for surgeons and hospital administrators who may be hesitant to adopt new technology. It signals that the device has moved beyond the early adopter phase and has built a foundation of clinical use and reliability. For a company like Elevation Spine, each implantation is not just a sale but, as Gilbride emphasized, a crucial piece of feedback that fuels its R&D engine and builds a moat of real-world data around its platform.

From Engineering to Patient Outcomes

While surgeons and industry analysts focus on procedural efficiency and market share, the ultimate measure of success for any medical device is its impact on patient well-being. The design philosophy behind the Saber-C system translates directly into potential patient benefits. A streamlined surgical workflow can lead to shorter operative times and reduced time under anesthesia, which are universally beneficial.

The most significant patient-centric advantage, supported by broader clinical literature on zero-profile devices, is the reduced risk of dysphagia. Difficulty swallowing can be a distressing and persistent issue following ACDF surgery, impacting a patient's quality of life and recovery. By minimizing the hardware profile at the front of the spine, systems like Saber-C directly mitigate a key cause of this complication. Furthermore, studies suggest that zero-profile systems may also lower the rates of other potential issues, such as adjacent segment disease, where the levels next to the fusion break down prematurely.

Regulatory Rigor and the Road Ahead

Elevation Spine has diligently navigated the rigorous regulatory landscape. The Saber-C system first earned FDA 510(k) clearance for single-level use and has since secured an expanded indication for two-level procedures. This two-level clearance is a critical commercial and clinical milestone, as it significantly broadens the patient population that can be treated with the device.

Like all medical implants, the system is not without potential risks. A review of the FDA's MAUDE database, which tracks adverse events, shows a single report related to the disassociation of components in a revision surgery. This serves as a reminder that implant complications can occur, a fact that is standard across all spinal hardware. Elevation Spine’s own documentation outlines these potential adverse effects, which are common to the product class.

Looking forward, the company is not resting on its laurels. It has already initiated a clinical registry to formally track the real-world radiographic and clinical outcomes of up to 200 patients, a move that demonstrates a commitment to long-term data collection and evidence building. Furthermore, Elevation Spine has announced that a next-generation update to the Saber-C system is anticipated for commercial launch later this year. While details remain under wraps, the company’s history of incorporating surgeon feedback suggests the updates will further enhance the system's performance and ease of use, ensuring that the next 5,000 implantations build on an even more refined platform.